Valion Bio (NASDAQ: VBIO) lines up $50,000 Series B financing step

What happened

Valion Bio, Inc. (NASDAQ: VBIO) said 3i, LP agreed on October 7, 2026, to buy 50 Series B preferred shares and related warrants for $50,000. The closing is subject to conditions in the side letter, and the warrants would cover 1,539 shares of common stock at $2.5520 each.

The side letter also gives 3i the option, but not the obligation, to buy up to 1,650 Series B preferred shares and related warrants for up to $1.65 million. The broader Series B purchase agreement already covers up to 8,400 Series B preferred shares and up to $8.4 million in a series of closings.

The same exhibit says 3i had already bought 13,637 Series C preferred shares for $13.64 million and can still buy up to 23,863 more for up to $23.86 million. It also references a senior secured convertible note with original principal of $16.25 million and a warrant for 182,129 shares.

Key numbers

Metric	Latest	Change	Source
Series B preferred shares to be issued at the closing	50 shares		SEC Exhibit 10.1
Series B warrants underlying common stock	1,539 shares		SEC Exhibit 10.1
Aggregate purchase price for the closing	$50,000		SEC Exhibit 10.1
Series B option under the side letter	up to 1,650 shares		SEC Exhibit 10.1
Series B option purchase price under the side letter	up to $1.65 million		SEC Exhibit 10.1
Initial exercise price for the closing warrants	$2.5520 per share		SEC Exhibit 10.1

Read more: Valion Bio (VBIO) stock analysis and investment case

Why it matters

OptimistFi's case is that VBIO is only attractive as a financed biotech option, so cash access and asset progress have to outrun burn and dilution. This filing keeps financing access alive, but the new tranche is small compared with the larger Series B and Series C amounts already in the exhibit.

The comparison matters because the new $50,000 tranche is only a sliver of the up to $8.4 million Series B authorization and the up to $75 million Series C program. That is supportive, but the side letter is still conditional, so it does not by itself show completed cash or less dilution.

The filing also sets a $2.5520 exercise price for the closing warrants, which leaves potential dilution if the securities are exercised.

Browse: stock research on every company OptimistFi covers

What's next

The next step is whether 3i satisfies or waives the stated closing conditions and funds the $50,000 purchase. If that happens, Valion Bio must deliver the closing shares, the closing warrants and the price-adjustment notice described in the side letter.

A completed closing would confirm this tranche of financing, while a failure to close would leave the transaction only as a conditional agreement. Either way, the filing's immediate value is in showing another funding route rather than a finished capital raise.

More from OptimistFi